What is the difference between Rasagiline and Selegiline?

Rasagiline (Rasagiline) and selegiline are approved by the U.S. Food and Drug Administration (FDA) called monoamine oxidase type B inhibitors (MAO-BIs) . Both are relatively selective and irreversible, but have some significant differences mainly in their metabolites: amphetamine derivatives and aminoindans. Selegiline is the first selective MAO-B inhibitor. It is partially metabolized in the body to l-methamphetamine (l-methamphetamine) and inhibits the reuptake of the neurotransmitters dopamine and norepinephrine. Rasagiline is metabolized to 1(R)-aminoindan, which does not have amphetamine-like characteristics and has neuroprotective properties in cellular and animal models. The symptomatic effects of both MAO-BIs have been well documented in prospective RCTs of both drugs in early Parkinson's disease.